Experts and Doctors on antineoplastic agents in Salzburg, Austria


Locale: Salzburg, Austria
Topic: antineoplastic agents

Top Publications

  1. Ganghammer S, Gutjahr J, Hutterer E, Krenn P, Pucher S, Zelle Rieser C, et al. Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. Haematologica. 2016;101:e99-102 pubmed publisher
  2. Mikes R, Jordan F, Hutarew G, Studnicka M. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer. 2015;90:614-6 pubmed publisher
    ..To our knowledge, this the first report of first line treatment of full squamous ALK-positive NSCLC with crizotinib. ..
  3. Hofbauer S, Krenn P, Ganghammer S, Asslaber D, Pichler U, Oberascher K, et al. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood. 2014;123:2181-8 pubmed publisher
    ..Collectively, our data suggest a dynamic regulation of Rac1 function in the CLL microenvironment. Rac inhibition could be of clinical use by selectively interfering with CLL cell proliferation and chemoresistance. ..
  4. Mayr C, Wagner A, Loeffelberger M, Br├╝ckner D, Jakab M, Berr F, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7:745-58 pubmed publisher
    ..In addition, PTC-209 reduced sphere formation and, in a cell line-dependent manner, aldehyde dehydrogease-1 positive cells. We conclude that PTC-209 might be a promising drug for future in vitro and in vivo studies in BTC. ..
  5. Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf A. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene. 2013;32:5574-81 pubmed publisher
    ..These results reveal a previously unknown mode of action of IMQ in the treatment of BCC and also suggest a role for ADORAs in the regulation of oncogenic HH signalling. ..
  6. Berlanda J, Kiesslich T, Engelhardt V, Krammer B, Plaetzer K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J Photochem Photobiol B. 2010;100:173-80 pubmed publisher
    ..Among all photosensitizers Photofrin has most clinical approvals and serves as standard. ..
  7. Bezan A, Hohla F, Meissnitzer T, Greil R. Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer. 2013;13:618 pubmed publisher
    ..This case suggests that treatment with catumaxomab does not only improve quality of life by local suppression of malignant ascites but also might have a systemic antitumor effect. ..
  8. Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C, et al. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012;8:15-29 pubmed
    ..Further in vivo investigation of these drugs as well as of new Wnt inhibitors may provide a promising approach for targeted therapy of this difficult-to-treat tumour. ..
  9. Wurstbauer K, Weise H, Deutschmann H, Kopp P, Merz F, Studnicka M, et al. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ? 80 Gy in standard fractionation. Strahlenther Onkol. 2010;186:551-7 pubmed publisher
    ..A higher potential of radiation therapy might be reached by accelerated fractionation regimens. ..

More Information


  1. Krammer B, Verwanger T. Molecular response to hypericin-induced photodamage. Curr Med Chem. 2012;19:793-8 pubmed
    ..The different modes of cellular responses depend mainly on the PDT-protocol, photosensitizer localisation, cellular damage protection and the available intracellular energy. ..
  2. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010;107:16228-33 pubmed publisher
    ..In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles. ..
  3. Neureiter D, Zopf S, Leu T, Dietze O, Hauser Kronberger C, Hahn E, et al. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol. 2007;42:103-16 pubmed
    ..These compounds may therefore be suitable as adjunctive therapeutic agents in the treatment of pancreatic cancer. ..
  4. Gruber W, Hutzinger M, Elmer D, Parigger T, Sternberg C, Cegielkowski L, et al. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 2016;7:7134-48 pubmed publisher
    ..The results support the use of DYRK1B antagonists for the treatment of HH/GLI-associated cancers where SMO inhibitors fail to demonstrate therapeutic efficacy. ..
  5. Jawhar M, Schwaab J, Naumann N, Horny H, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137-145 pubmed publisher
    ..In midostaurin-treated advSM patients, the complexity and dynamics of mutational profiles significantly affect response, progression, and prognosis. ..
  6. Eisterer W, Piringer G, de Vries A, Ofner D, Greil R, Tschmelitsch J, et al. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Anticancer Res. 2017;37:2683-2691 pubmed
  7. Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, et al. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS ONE. 2017;12:e0180995 pubmed publisher
    ..By combining these factors to create a score for OS, it is possible to distinguish a group of patients with significantly improved survival and define those most likely to have no benefit from cetuximab treatment. ..
  8. Somasundaram R, Zhang G, Fukunaga Kalabis M, Perego M, Krepler C, Xu X, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017;8:607 pubmed publisher
    ..Resistance to BRAFV600E inhibitors often occurs in melanoma patients. Here, the authors describe a potential mechanism of acquired drug resistance mediated by tumor-associated B cells-derived IGF-1. ..